The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Year: 2004
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Blood
Authors: R. Forstpointner, Martin Dreyling, Roland Repp, Sandra Hermann, Annette Hänel, Bernd Metzner, Christiane Pott, Frank Hartmann, Frank Rothmann, Robert Rohrberg, Hans-Peter Böck, Hannes Wandt, Michael Unterhalt, Wolfgang Hiddemann
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2163790170